TGF-β signaling has been considered a therapeutic target for many cancers, and our results demonstrate that the MUC1 oncogene, upstream of the TGF-β signaling is a more attractive therapeutic target for HCC. This evidence concerns the gene MUC1 and hepatocellular carcinoma.